7 results about "Insulinlike growth factor" patented technology

The present invention provides methods and compositions for the treatment of chronic lung disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1).

The invention relates to the technical field of agricultural science, and particularly discloses preparation and application of a composite polypeptide growth-promoting supplement liquid for livestock and poultry. The composition comprises a plurality of active polypeptides such as recombinant human epidermal growth factors, trefoil peptides, insulin-like growth factors and the like, vitamins A, E, C and B, and is supplemented with recombinant collagen peptides, marine source acidic polysaccharides and a composite carrier consisting of hydroxypropyl-beta-cyclodextrin, trehalose and sodium hyaluronate. The preparation method comprises the following steps: respectively carrying out independent shunt pretreatment on the polypeptide component and the vitamin component, integrating through a programmed gradient compounding process and a dynamic pH regulation process, and finally carrying out fine filtration and sterile filling to obtain the product. The composition can be used for preparing a feed or drinking water additive for promoting the growth of livestock and poultry, maintaining intestinal health and improving the feed utilization rate, and has the advantages of stable components and good activity maintaining effect; according to the preparation method, the long-acting stability of the composite system is realized by optimizing the process sequence and conditions.

Methods are provided for detecting and / or quantifying insulin-like growth factor-2 (IGF-2) variant(s) in a sample. Methods provided herein are further directed to using the detected ion or ions to determine the presence of IGF2 variant(s) in the sample.

Provided here are methods for treating a cytokine storm in a subject. One such method includes the administration of a therapeutically effective amount of an Insulin-like Growth Factor (IGF-1), a Ca2+-release-activated Ca2+ (CRAC) channel inhibitor, or combinations thereof. Methods include treatment of acute lung injury or acute kidney injury with a therapeutically effective amount of 3,5-bis(trifluoromethyl) pyrazole derivative or teriflunomide, either individually or in combination with IGF-1.

The present invention provides, among other things, methods and compositions for treating Chronic Lung Disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1) or an agonist or an analog thereof.